Listed

Resmed Inc: Form 10-Q for the period ended Dec 31, 2024

Filed with the SEC on Jan 31, 2025 and accepted by EDGAR at Jan 30, 2025, 19:08 ET.

Share

Management's discussion and analysis

As filed, 1,507 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Purchases of equity securities. The following table summarizes our purchases of common stock for the three months ended December 31, 2024:

Period Total Number of Shares Purchased Average Price Paid per Share (USD) Total Number of Shares Purchased as Part of Publicly Announced Programs Maximum Number of Shares that May Yet Be Purchased Under the Program
October 1 - 31, 2024 96,000 244.60 42,982,063 11,733,950
November 1 - 30, 2024 210,850 244.34 43,192,913 11,523,100
December 1 - 31, 2024 — — 43,192,913 11,523,100
Total 306,850 $244.42 43,192,913 11,523,100

On February 21, 2014, our board of directors approved our current share repurchase program, authorizing us to acquire up to an aggregate of 20.0 million shares of our common stock. The program allows us to repurchase shares of our common stock from time to time for cash in the open market, or in negotiated or block transactions, as market and business conditions warrant and subject to applicable legal requirements. The share repurchase program may be accelerated, suspended, delayed or discontinued at any time at the discretion of our board of directors. All share repurchases after February 21, 2014 have been executed under this program. Since approval of the share repurchase program in 2014 through December 31, 2024, we have repurchased a total of 8.5 million shares under this repurchase program for an aggregate of $687.7 million.

Controls and procedures

As filed, 1,803 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in our reports made pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance management necessarily was required to apply its judgment in evaluating the cost benefit relationship of possible controls and procedures.

As required by Rule 13a-15(b) of the Exchange Act, we carried out an evaluation, under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of December 31, 2024.

There has been no change in our internal control over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Risk factors

As filed, 389 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The discussion of our business and operations should be read together with the risk factors contained in our annual report on Form 10-K for the fiscal year ended June 30, 2024, which was filed with the SEC and describe various material risks and uncertainties to which we are or may become subject. As of December 31, 2024, there have been no further material changes to such risk factors.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2024-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2024-10-01 to 2024-12-31$1.28bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue6 months2024-07-01 to 2024-12-31$2.51bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2024-10-01 to 2024-12-31$530.8mus-gaap:CostOfGoodsAndServicesSold
Cost of revenue6 months2024-07-01 to 2024-12-31$1.04bnus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2024-10-01 to 2024-12-31$751.3mus-gaap:GrossProfit
Gross profit6 months2024-07-01 to 2024-12-31$1.47bnus-gaap:GrossProfit
Research and development3 months2024-10-01 to 2024-12-31$81.4mus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2024-07-01 to 2024-12-31$160.9mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2024-10-01 to 2024-12-31$241.6mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative6 months2024-07-01 to 2024-12-31$480.6mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2024-10-01 to 2024-12-31$417.2mus-gaap:OperatingIncomeLoss
Operating income6 months2024-07-01 to 2024-12-31$804.6mus-gaap:OperatingIncomeLoss
Income tax3 months2024-10-01 to 2024-12-31$73.7mus-gaap:IncomeTaxExpenseBenefit
Income tax6 months2024-07-01 to 2024-12-31$145.8mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2024-10-01 to 2024-12-31$344.6mus-gaap:NetIncomeLoss
Net income6 months2024-07-01 to 2024-12-31$656.0mus-gaap:NetIncomeLoss
Diluted EPS3 months2024-10-01 to 2024-12-31$2.34us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2024-07-01 to 2024-12-31$4.45us-gaap:EarningsPerShareDiluted
Basic EPS3 months2024-10-01 to 2024-12-31$2.35us-gaap:EarningsPerShareBasic
Basic EPS6 months2024-07-01 to 2024-12-31$4.47us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2024-10-01 to 2024-12-31147,481,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2024-07-01 to 2024-12-31147,520,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2024-07-01 to 2024-12-31$634.2mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure6 months2024-07-01 to 2024-12-31$38.5mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Dividends paid6 months2024-07-01 to 2024-12-31$155.6mus-gaap:PaymentsOfDividends
Share repurchases6 months2024-07-01 to 2024-12-31$125.0mus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2024-12-31$521.9mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2024-12-31$2.84bnus-gaap:AssetsCurrent
Total assetsAt period end2024-12-31$7.14bnus-gaap:Assets
Current liabilitiesAt period end2024-12-31$852.0mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2024-12-31$1.89bnus-gaap:Liabilities
Long-term debtAt period end2024-12-31$662.9mus-gaap:LongTermDebt
Short-term borrowingsAt period end2024-12-31$9.9mus-gaap:ShortTermBorrowings
Shareholders' equityAt period end2024-12-31$5.25bnus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0000943819-25-000004. Last ingested by Listed: Nov 14, 2026, 17:21 ET. Listed shows no prices and gives no investment advice.